An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling.
Vaccine
; 37(24): 3146-3150, 2019 05 27.
Article
en En
| MEDLINE
| ID: mdl-31047675
ABSTRACT
Over the past decade, chikungunya virus (CHIKV) has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Réunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
/
3_ND
Problema de salud:
1_doencas_transmissiveis
/
2_enfermedades_transmissibles
/
3_chikungunya
Asunto principal:
Vacunas Virales
/
Adenoviridae
/
Adyuvantes Inmunológicos
/
Fiebre Chikungunya
Límite:
Animals
Idioma:
En
Revista:
Vaccine
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos